BeOne Medicines (ONC) Total Debt (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Total Debt data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Total Debt rose 16.78% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 16.78% YoY) and the FY2025 annual result came in at $1.0 billion, changed 0.12% from the prior year.
• Total Debt improved to $1.1 billion in Q1 2026 per ONC's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Total Debt topped out at $1.6 billion in Q3 2025 and bottomed at $209.1 million in Q4 2022.
• The 5-year median for Total Debt is $923.6 million (2025), against an average of $842.4 million.
• The widest annual swing landed in 2022, when Total Debt plunged 66.78%; it then surged 323.62% in 2023.
• Tracing ONC's Total Debt over 5 years: stood at $209.1 million in 2022, then jumped by 323.62% to $886.0 million in 2023, then increased by 14.9% to $1.0 billion in 2024, then rose by 0.12% to $1.0 billion in 2025, then rose by 5.83% to $1.1 billion in 2026.
• Per Business Quant, the three latest ONC Total Debt figures stand at $1.1 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.6 billion (Q3 2025).

Peer Comparison